In brief
Under the new deal, the Sacklers will contribute $6.5 billion, while Purdue will pay $900 million, aiming to fund addiction treatment and crisis prevention efforts across the nation.
Purdue Pharma, alongside the Sackler family, has reached a significant $7.4 billion settlement aimed at addressing the widespread impact of its prescription painkiller OxyContin. This agreement marks an increase of over $1 billion from a previous settlement proposal that the US Supreme Court rejected in 2024, according to reports from agencies like AP and Reuters.The settlement composition includes a payment of up to $6.5 billion by the Sackler family and an additional $900 million from Purdue itself. The notorious opioid OxyContin has been identified as a major contributor to the opioid epidemic in America, often leading users to transition to more dangerous drugs like heroin, while generating significant profits for its creators, the Sackler family.In a statement, Purdue expressed satisfaction with the newly negotiated terms, highlighting that the settlement will provide substantial support for opioid addiction treatment and preventive measures in the United States. "This agreement will deliver billions of dollars to compensate victims, combat the opioid crisis, and provide essential treatments and rescue medicines that can save lives," they said.While the settlement is seen as a pivotal step towards addressing the opioid crisis, it still requires court approval, with some details pending clarification. The deal is part of a broader series of lawsuits involving various governments and tribal authorities aiming to hold companies accountable for the epidemic's repercussions. Reportedly, the current federal administration is expected to endorse the agreement.Connecticut Attorney General William Tong spoke on behalf of victims, emphasizing the importance of closure. "It's not just about the money," Tong remarked, indicating that financial compensation alone cannot right the wrongs inflicted by the epidemic. Under the terms of the previously rejected settlement, the Sacklers were offered immunity from future lawsuits, which raised concerns. Current court constraints that prevent lawsuits against Sackler family members are poised to expire, although a bankruptcy court judge has been asked to extend this protection through February as final details are established.Among those impacted is Kara Trainor, a woman who has successfully battled addiction to OxyContin for 17 years. She voiced her appreciation for the new agreement, stating, "Everything in my life is shaped by a company that put profits over human lives."Purdue Pharma was once a household name as the manufacturer of OxyContin, a drug marketed as safe despite known risks of addiction and abuse. Since the drug's introduction, opioid overdose deaths have risen alarmingly, reaching tens of thousands each year. Court documents indicate that the Sackler family was cognizant of legal risks associated with their product, withdrawing approximately $11 billion from the company before its bankruptcy, leading to significant challenges in recovering those funds.
